A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice

European Journal of Pharmacology

Volumn 561, Issue 1-3, 2007, Pages 105-111

  Cyrus, Tillmann ^b   Yao, Yuemang ^a   Ding, Tao ^a   Dogné, Jean Michel ^c   Praticò, Domenico ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF NAMUR   (Belgium)

Author keywords

Atherosclerosis; Cycloxygenase; Thromboxane

Indexed keywords

APOLIPOPROTEIN E; BM 573; LOW DENSITY LIPOPROTEIN RECEPTOR; PLACEBO; PROSTACYCLIN; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE COURSE; MEDIATOR RELEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; AORTA; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EPOPROSTENOL; MALE; MICE; MICE, INBRED C57BL; PLATELET AGGREGATION INHIBITORS; RECEPTORS, LDL; RECEPTORS, THROMBOXANE; SULFONYLUREA COMPOUNDS; THROMBOXANE A2; TRIGLYCERIDES;

EID: 33947318413     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.12.024     Document Type: Article

References (30)

1. Antithrombotic Trialist' Collaboration. Collaborative meta-analysis of randomized clinical trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Br. Med. J. 324 (2002) 71-86
2. Babaev V.R., Ding L., Reese J., Morrow J.D., Breyer M.D., Dey S.K., Fazio S., and Linton M.F. Cycloxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E-deficient and Low-density lipoprotein receptor-null mice. Circulation 113 (2006) 108-117
3. Belton O., Byrne D., Kearny D., Leahy A., and Fitzgerald D.J. Cyclo-oxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102 (2000) 840-845
4. Belton O., Duffy A., Toomey S., and Fitzgerald D.J. Cyclo-oxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 108 (2003) 3017-3023
5. Cayatte A.J., Du Y., Oliver-Kraninski J., Lavielle G., Verbeuren T.J., and Cohen R.A. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apoE-deficient mice. Evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1724-1728
6. 2 but not of systemic prostacyclin by controlled-release aspirin. N. Engl. J. Med. 325 (1991) 1137-1141
7. Cyrus T., Tang L.X., Rokach J., FitzGerald G.A., and Praticò D. Lipid peroxidation and platelet activation in murine atherosclerosis. Circulation 104 (2001) 1940-1945
8. Cyrus T., Sung S., Zhao L., Funk C.D., Tang S., and Praticò D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 106 (2002) 1282-1287
9. Cyrus T., Yao Y., Tung L., and Praticò D. Regression of established atherosclerosis in low density lipoprotein deficient mice by low-dose aspirin. Atherosclerosis 184 (2006) 8-14
10. Dogne J.M., Hanson J., and Pratico D. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol. Sci. 26 (2005) 639-644
11. Dogne J.M., Hanson J., Leval X., Pratico D., Pace-Asciak C., Drion P., Bernard P., and Ruan K. From the design to the clinical application of thromboxane modulators. Curr. Pharm. Des. 12 (2006) 903-923
12. Egan K.M., Wang M., Lucitt M.B., Zukas A.M., Pure E., Lawson J.A., and FitzGerald G.A. Cycloxygenases, thromboxane, and atherosclerosis. Plaque destabilization by cycloxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111 (2005) 334-342
13. Ghuysen A., Lambermont B., Dogne J.M., Kolh P., Tchana-Sato V., Morimont P., Magis D., Hanson J., Segers P., and D'Orio V. Effect of BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist in a porcine model of acute pulmonary embolism. J. Pharmacol. Exp. Ther. 310 (2004) 964-972
14. Ghuysen A., Dogne J.M., Chiap P., Rolin S., Masereel B., Lambermont B., Kolh P., Tchana-Sato V., Hanson J., and D'Orio V. Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane antagonist and synthase inhibitor. Cardiovasc. Drug Rev. 23 (2005) 1-14
15. 2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J. Clin. Invest. 114 (2004) 784-794
16. Lambermont B., Kolh P., Dogne J.M., Ghuysen A., Tchana-Sato V., Morimont P., Benoit P., Gerard P., Masereel B., Limet R., and D'Orio V. Effects of U-46619 on pulmonary hemodynamic before and after administration of BM-573 a novel thromboxane A2 inhibitor. Arch. Physiol. Biochem. 111 (2003) 217-223
17. Lambermont B., Kolh P., Ghuysen A., Segers P., Dogne J.M., Tchan-Sato V., Morimont P., Benoit P., Gerard P., Masereel B., and D'Orio V. Effect of a novel thromboxane A2 inhibitor on right ventricular-arterial coupling in endotoxic shock. Shock 21 (2004) 45-51
18. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-872
19. -/- mouse model. Arterioscler. Thromb. Vasc. Biol. 24 (2004) e73
20. McGeers P.L., McGeer E.G., and Yasojima K. Expression of COX-1 and COX-2 mRNAs in atherosclerotic plaques. Exp. Gerontol. 37 (2002) 925-929
21. Praticò D., Cyrus T., Li H., and FitzGerald G.A. Endogenous biosynthesis of thromboxane and prostacyclin in two distinct murine models of atherosclerosis. Blood 96 (2000) 3823-3826
22. Praticò D., Cyrus T., Zhang Z., Li H., and FitzGerald G.A. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 3358-3363
23. Rolin S., Dogne J.M., Michaux C., Delarge J., and Masereel B. Activity of a novel dual thromboxane A2 receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Prostaglandins Leukot. Essent. Fat. Acids 65 (2001) 67-72
24. Rolin S., Petein M., Tchana-Sato V., Dogne J.M., Lambermont B., Ghuysen A., Kolh P., and Masereel B. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis. J. Pharmacol. Exp. Ther. 306 (2003) 59-65
25. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
26. Saini H.K., Xu Y.J., Arneja A.S., Tappia P.S., and Dhalla N.S. Pharmacological basis of different targets for the treatment of atherosclerosis. J. Cell. Mol. Med. 9 (2005) 818-839
27. 2α mediate inflammatory tachycardia. Nat. Med. 11 (2005) 562-566
28. 2α-III. Circulation 112 (2005) 2867-2874
29. Worth N.F., Berry C.L., Thomas A.C., and Campbell J.H. S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis 183 (2005) 65-73
30. Zhuge X., Arai H., Xu Y., Murayama T., Kobayashi T., Narumiya S., Kita T., and Yokode M. Protection of atherogenesis in thromboxane A2 receptor-deficient mice is associated with thromboxane A2 receptor in bone marrow-derived cells. Biochem. Biophys. Res. Commun. 351 (2006) 865-871